Alnylam shares touch 52-week low as biotech sell-off weighs on RNAi pioneer

Shares of Alnylam Pharmaceuticals (ALNY) hit a 52-week low of $273.03 last month, extending a steep decline that has seen the RNAi drug developer shed nearly 29% of its value since the start of the year and around 13% over the past 12 months, as broader pressure on the biotechnology sector compounds company-specific concerns over drug development timelines and regulatory uncertainty.

The stock, which has become a bellwether for the RNA interference therapeutics space, is trading sharply below analyst consensus price targets.